» Authors » Kent C Shih

Kent C Shih

Explore the profile of Kent C Shih including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 1221
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Falchook G, Battiste J, Kalra A, Shastry M, Finney L, Hoekstra S, et al.
Neurooncol Adv . 2025 Feb; 7(1):vdae220. PMID: 39925637
Background: To improve survival in patients with high-grade glioma, INC280 (capmatinib) a highly selective and potent oral inhibitor of the MET receptor with robust central nervous system (CNS) penetration, was...
2.
DAngelo S, Bhatia S, Brohl A, Hamid O, Mehnert J, Terheyden P, et al.
J Immunother Cancer . 2020 May; 8(1). PMID: 32414862
Background: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with a high risk of metastasis. In 2017, avelumab (anti-programmed death-ligand 1 (PD-L1)) became the first approved treatment...
3.
Spigel D, Shipley D, Waterhouse D, Jones S, Ward P, Shih K, et al.
Oncologist . 2019 Aug; 24(12):e1409-e1416. PMID: 31420467
Background: This randomized, double-blinded, phase II trial evaluated the efficacy of carboplatin and pemetrexed plus either apatorsen, an antisense oligonucleotide targeting heat shock protein (Hsp) 27 mRNA, or placebo in...
4.
DAngelo S, Hunger M, Brohl A, Nghiem P, Bhatia S, Hamid O, et al.
Cancer Immunol Immunother . 2019 Feb; 68(4):609-618. PMID: 30721341
Background: Response rates are primary endpoints in many oncology trials; however, correlation with overall survival (OS) is not uniform across cancer types, treatments, or lines of therapy. This study explored...
5.
de Bono J, De Giorgi U, Nava Rodrigues D, Massard C, Bracarda S, Font A, et al.
Clin Cancer Res . 2018 Jul; 25(3):928-936. PMID: 30037818
Purpose: PI3K-Akt-mTOR and androgen receptor (AR) signaling are commonly aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN loss associating with poor prognosis. We therefore conducted a phase Ib/II...
6.
Spigel D, Burris 3rd H, Greco F, Shih K, Gian V, Lipman A, et al.
Cancer . 2018 Apr; 124(11):2355-2364. PMID: 29645086
Background: This study compared the efficacy and safety of treatment with erlotinib plus pazopanib versus erlotinib plus placebo in patients with previously treated advanced non-small cell lung cancer (NSCLC). Methods:...
7.
Hainsworth J, Waterhouse D, Shih K, Boccia R, Priego V, McCleod M, et al.
Lung Cancer . 2018 Mar; 118:6-12. PMID: 29572004
Objectives: The combination of pemetrexed and carboplatin is a standard first-line treatment for patients with advanced NSCLC. In this pilot phase II trial, we evaluated the feasibility of using pemetrexed...
8.
Kaufman H, Russell J, Hamid O, Bhatia S, Terheyden P, DAngelo S, et al.
J Immunother Cancer . 2018 Jan; 6(1):7. PMID: 29347993
Background: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel...
9.
Spigel D, Rubin M, Gian V, Shipley D, Burris 3rd H, Kosloff R, et al.
Lung Cancer . 2017 Nov; 113:79-84. PMID: 29110854
Purpose: To evaluate the efficacy of erlotinib, continued after tumor progression, plus sorafenib versus sorafenib alone in patients with refractory metastatic non-small cell lung cancer (NSCLC) who previously benefitted from...
10.
Kaufman H, Russell J, Hamid O, Bhatia S, Terheyden P, DAngelo S, et al.
Lancet Oncol . 2016 Sep; 17(10):1374-1385. PMID: 27592805
Background: Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in patients with advanced disease. Current standard care uses various cytotoxic chemotherapy regimens, but responses are seldom...